The antitumor activity of PD-1 can be aided by an SGLT2 inhibitor, and the synergistic effect stimulates the infiltration of CD4+ and CD8+T lymphocytes into the OS tumour microenvironment (142). The gene discussed is SLC5A2; the disease is neoplasm.